IL34 and Autoimmunity: When we assessed the therapeutic potential of IL‐34 therapy in autoimmunity in the EAE model, we observed that the injection of an adenovirus coding for murine IL‐34 in association with a suboptimal dose of rapamycin led to a delayed EAE development compared to the control groups, that is, null adenovirus associated or not with rapamycin (Figure 4C, left).